25th Apr 2018 12:17
LONDON (Alliance News) - Cell-based medicine and life science company MaxCyte Inc on Wednesday announced the appointment of Claudio Dansky Ullmann as its new chief medical officer.
Dansky Ullmann, originally from Argentina, will be responsible for the clinical development of MaxCyte's CARMA drug programme as its first candidate, MCY-M11, nears entering the clinic later this year, it said.
Most recently, Dansky Ullmann was senior vice-president & head of clinical development at Infinity Pharmaceuticals. He was before that a senior medical director & global clinical lead for oncology clinical research at Japanese firm Takeda Pharmaceutics.
Chief Executive Doug Doerfler said: "We are thrilled to welcome Claudio to the MaxCyte team. His broad experience in cancer therapy drug development will be invaluable at this stage in MaxCyte's evolution from a cell engineering technology company to a drug developer with a pipeline of CARMA drug candidate programs.
"Furthermore, with his deep understanding of the development of immuno-oncology therapies and other cancer treatments, Claudio will help us to advance our Flow Electroporation technology to enable our partners to make important medical breakthroughs."
Shares were down 1.6% on Wednesday at 246.00 pence each.
Related Shares:
MaxCyte